The Beneficial Effect of Suramin on Monocrotaline-induced Pulmonary Hypertension in Rats

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Oct 22

PMID 24143201

Citations 6

Authors

Mohamed Izikki

Olaf Mercier

Florence Lecerf

Lauriane Lubert Guin

Eric Hoang

Peter Dorfmuller

Frederic Perros

Marc Humbert

Gerald Simonneau

Philippe Dartevelle

Elie Fadel

Saadia Eddahibi

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary hypertension (PH) is a progressive disorder characterized by an increase in pulmonary artery pressure and structural changes in the pulmonary vasculature. Several observations indicate that growth factors play a key role in PH by modulating pulmonary artery smooth muscle cell (PA-SMC) function. In rats, established monocrotaline-induced PH (MCT-PH) can be reversed by blocking platelet-derived growth factor receptors (PDGF-R), epidermal growth factor receptors (EGF-R), or fibroblast growth factor receptors (FGF-R). All these receptors belong to the receptor tyrosine kinase (RTK) family.

Methods And Results: We evaluated whether RTK blockade by the nonspecific growth factor inhibitor, suramin, reversed advanced MCT-PH in rats via its effects on growth-factor signaling pathways. We found that suramin inhibited RTK and ERK1/2 phosphorylation in cultured human PA-SMCs. Suramin inhibited PA-SMC proliferation induced by serum, PDGF, FGF2, or EGF in vitro and ex vivo. Treatment with suramin from day 1 to day 21 after monocrotaline injection attenuated PH development, as shown by lower values for pulmonary artery pressure, right ventricular hypertrophy, and distal vessel muscularization on day 21 compared to control rats. Treatment with suramin from day 21 to day 42 after monocrotaline injection reversed established PH, thereby normalizing the pulmonary artery pressure values and vessel structure. Suramin treatment suppressed PA-SMC proliferation and attenuated both the inflammatory response and the deposition of collagen.

Conclusions: RTK blockade by suramin can prevent MCT-PH and reverse established MCT-PH in rats. This study suggests that an anti-RTK strategy that targets multiple RTKs could be useful in the treatment of pulmonary hypertension.

Citing Articles

Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.

Jasinska-Stroschein M, Glajzner P Int J Mol Sci. 2024; 25(23).

PMID: 39684570 PMC: 11641621. DOI: 10.3390/ijms252312858.

Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells.

Xiong Y, Wang Y, Yang T, Luo Y, Xu S, Li L Am J Cardiovasc Drugs. 2023; 23(5):497-518.

PMID: 37524956 DOI: 10.1007/s40256-023-00596-3.

Link between sterile inflammation and cardiovascular diseases: Focus on cGAS-STING pathway in the pathogenesis and therapeutic prospect.

Du Y, Zhang H, Nie X, Qi Y, Shi S, Han Y Front Cardiovasc Med. 2022; 9:965726.

PMID: 36072862 PMC: 9441773. DOI: 10.3389/fcvm.2022.965726.

TCP1γ Subunit Is Indispensable for Growth and Infectivity of Leishmania donovani.

Yadav S, Kuldeep J, Siddiqi M, Goyal N Antimicrob Agents Chemother. 2020; 64(8).

PMID: 32457112 PMC: 7526847. DOI: 10.1128/AAC.00669-20.

A simple method to assess in vivo proliferation in lung vasculature with EdU: the case of MMC-induced PVOD in rat.

Fabrice A, Benoit R, Valerie N, Lau E, Sebastien B, Frederic P Anal Cell Pathol (Amst). 2015; 2015:326385.

PMID: 26345623 PMC: 4546736. DOI: 10.1155/2015/326385.

References

Cowan K, Jones P, Rabinovitch M . Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res. 1999; 84(10):1223-33. DOI: 10.1161/01.res.84.10.1223. View

Asadi Karam G, Rasaee M, Mahmoodi M, Khaksari M . Inhibition of proteinase 3 (PR3) by suramin and fetal calf serum (FCS): effect of PR3 and suramin on Chinese hamster ovary cells (CHO-cells). Pak J Pharm Sci. 2005; 18(3):46-8. View

de Souza O, Sakamoto T, Kimura H, Koda R, Gabrielian K, Spee C . Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. Ophthalmologica. 1995; 209(4):212-6. DOI: 10.1159/000310616. View

Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P . Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest. 2009; 119(3):512-23. PMC: 2648677. DOI: 10.1172/JCI35070. View

Raj P, Marcus E, Rein R . Conformational requirements of suramin to target angiogenic growth factors. Angiogenesis. 2003; 2(2):183-99. DOI: 10.1023/a:1009244623717. View

Zanghi J, Renner W, Bailey J, Fussenegger M . The growth factor inhibitor suramin reduces apoptosis and cell aggregation in protein-free CHO cell batch cultures. Biotechnol Prog. 2000; 16(3):319-25. DOI: 10.1021/bp0000353. View

Shi W, Eidelman D, Michel R . Differential relaxant responses of pulmonary arteries and veins in lung explants of guinea pigs. J Appl Physiol (1985). 1998; 83(5):1476-81. DOI: 10.1152/jappl.1997.83.5.1476. View

Chan Y, Li Y, Foster W, Horaguchi T, Somogyi G, Fu F . Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol (1985). 2003; 95(2):771-80. DOI: 10.1152/japplphysiol.00915.2002. View

Mekontso-Dessap A, Kirsch M, Guignambert C, Zadigue P, Adnot S, Loisance D . Vascular-wall remodeling of 3 human bypass vessels: organ culture and smooth muscle cell properties. J Thorac Cardiovasc Surg. 2006; 131(3):651-8. DOI: 10.1016/j.jtcvs.2005.08.048. View

10.

Rabinovitch M, Gamble W, NADAS A, Miettinen O, Reid L . Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol. 1979; 236(6):H818-27. DOI: 10.1152/ajpheart.1979.236.6.H818. View

11.

Hosang M . Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem. 1985; 29(3):265-73. DOI: 10.1002/jcb.240290310. View

12.

Takano S, Gately S, Neville M, Herblin W, Gross J, Engelhard H . Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 1994; 54(10):2654-60. View

13.

HAWKING F . Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1978; 15:289-322. DOI: 10.1016/s1054-3589(08)60486-x. View

14.

Merklinger S, Jones P, Martinez E, Rabinovitch M . Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation. 2005; 112(3):423-31. DOI: 10.1161/CIRCULATIONAHA.105.540542. View

15.

Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, Zhuang S . Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol. 2011; 22(6):1064-75. PMC: 3103726. DOI: 10.1681/ASN.2010090956. View

16.

Williams L, Tremble P, Lavin M, Sunday M . Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. J Biol Chem. 1984; 259(8):5287-94. View

17.

Motzer R, Nanus D, OMoore P, Scher H, Bajorin D, Reuter V . Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res. 1992; 52(20):5775-9. View

18.

Ghofrani H, Morrell N, Hoeper M, Olschewski H, Peacock A, Barst R . Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010; 182(9):1171-7. PMC: 3001259. DOI: 10.1164/rccm.201001-0123OC. View

19.

Schermuly R, Dony E, Ghofrani H, Pullamsetti S, Savai R, Roth M . Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115(10):2811-21. PMC: 1236676. DOI: 10.1172/JCI24838. View

20.

Myers C, Cooper M, Stein C, Larocca R, Walther M, Weiss G . Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992; 10(6):881-9. DOI: 10.1200/JCO.1992.10.6.881. View